Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Blood

• Publication date

  2015-02-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2014-10-609032PMID 25593335PMCID PMC4335084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

  2014cited by this paper
• Improving Engraftment and Immune Reconstitution in Umbilical Cord Blood Transplantation

  2014cited by this paper
• Modelling Survival Data in Medical Research

  2014cited by this paper
• Use of composite endpoints in clinical trials

  2014cited by this paper
• Peripheral-blood stem cells versus bone marrow from unrelated donors.

  2012cited by this paper
• Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

  2011cited by this paper
• Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

  2011cited by this paper
• Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.

  2010cited by this paper
• Erratum to "A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model" [Computer Methods and Programs in Biomedicine 88 (2007) 95-101]

  2008cited by this paper
• Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.

  2007cited by this paper
• A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model

  2007cited by this paper
• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  2005cited by this paper
• Modelling Survival Data in Medical Research

  2004cited by this paper
• Modelling Survival Data in Medical Research (2nd ed.) (Book)

  2004cited by this paper
• Modelling Survival Data in Medical Research, Second Edition

  2003cited by this paper
• A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.

  2003cited by this paper
• Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.

  2002influential reference
• Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.

  1999cited by this paper
• Estimation of variance in Cox's regression model with shared gamma frailties.

  1997cited by this paper
• Frailty models for survival data

  1995cited by this paper
• Variance Calculations for Direct Adjusted Survival Curves, with Applications to Testing for No Treatment Effect

  1986cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowninfluential reference

• A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia.

  2026cites this paper
• Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?

  2026cites this paper
• Frailty as a prognostic factor in younger adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

  2026cites this paper
• Outcomes of DPB1 Mismatch in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Time to Move Past Chromosome 6?

  2026cites this paper
• Rforce: Random Forests for Composite Endpoints

  2026cites this paper
• Long-term survival gains after allogeneic hematopoietic stem cell transplant are driven by reductions in non-relapse mortality: A 35-Year Statewide Australian cohort study.

  2026cites this paper
• Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trial

  2026cites this paper
• Optimal GVHD Prophylaxis.

  2025cites this paper
• NK Alloreactivity Evaluation According to KIR‐HLA Interaction Models Influences the Outcome of Haploidentical Haematopoietic Stem‐Cell Transplantation Based on Post‐Transplant Cyclophosphamide

  2025cites this paper
• Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation

  2025cites this paper
• Microbiome-based prediction of allogeneic hematopoietic stem cell transplantation outcome

  2025cites this paper
• Outcomes of haploidentical stem cell transplantation in upfront and salvage settings for adult patients with severe aplastic anemia.

  2025cites this paper
• Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.

  2025cites this paper
• A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation

  2025cites this paper
• Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation

  2025cites this paper
• Post-transplant cyclophosphamide in haploidentical stem cell transplantation: evaluating the impact of transplant conditioning intensity

  2025cites this paper
• A win ratio approach for comparing graft‐versus‐host disease‐free, relapse‐free survival among alternative donors

  2025cites this paper
• HLA‐matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML

  2025cites this paper
• Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML

  2025cites this paper
• High Melphalan Exposure Increases the Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.

  2025cites this paper
• Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia

  2025cites this paper
• Exploring Outcomes by Ethnicity in Allogeneic Hematopoietic Cell Transplantation

  2025cites this paper
• Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin (ATLG) vs. Anti‐Thymocyte Globulin (ATG) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study

  2025cites this paper
• Posttransplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21

  2025cites this paper
• Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC

  2025influential citation
• Impact of graft‐versus‐host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation

  2025cites this paper
• Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

  2025cites this paper
• HCT-VTE-J Model to Predict Late-Onset Venous Thromboembolism after Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Single-Center Study.

  2025cites this paper
• Impact of graft‐versus‐host disease prophylaxis strategies on GvHD‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis

  2025cites this paper
• Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/PTCy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia.

  2025cites this paper
• Outcomes of adults older than 70 years of age undergoing allogeneic stem cell transplantation.

  2025cites this paper
• Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

  2025cites this paper
• Safety and efficacy of GVHD prophylaxis with mini-dose methotrexate in umbilical cord blood transplantation - NJHSG-CBT18 observational study.

  2025cites this paper
• Equivalent incidences of paediatric graft‐versus‐host disease regardless of donor–recipient matching in the era of modern prophylaxis agents

  2025cites this paper
• Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents

  2025cites this paper
• A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts

  2025cites this paper
• Comparative analysis of allogeneic hematopoietic cell transplantation in patients with therapy-related and de novo acute promyelocytic leukemia A retrospective study

  2025cites this paper
• Elevation of White Blood Cell Count after G-CSF-Combined Conditioning Predicts Relapse and Disease-Free Survival Following Single-Unit Cord Blood Transplantation for Myeloid Malignancies: WBC Elevation with G-CSF Conditioning Predicts Relapse after CBT.

  2025cites this paper
• Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  2025cites this paper
• Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity

  2025cites this paper
• Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms

  2025cites this paper
• Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation

  2024cites this paper
• Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia

  2024cites this paper
• Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide.

  2024cites this paper
• Impact of Race and Ethnicity on Outcomes after Umbilical Cord Blood Transplantation.

  2024cites this paper
• Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma

  2024cites this paper
• Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC

  2024cites this paper
• Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies

  2024cites this paper
• PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

  2024cites this paper
• Enhanced Survival of Chronic Myelomonocytic Leukemia-Dysplastic over Proliferative Subtype after Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review

  2024cites this paper
• Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study

  2024cites this paper
• Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia

  2024cites this paper
• Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study

  2024cites this paper
• Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

  2024cites this paper
• Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort.

  2024cites this paper
• Effects of total body irradiation on hematopoietic cell transplantation outcomes in pediatric acute myeloid leukemia with prior central nervous system involvement.

  2024cites this paper
• Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia

  2024cites this paper
• Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma

  2024cites this paper
• Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients

  2024cites this paper
• Comparison of melphalan dose in patients with myelodysplastic syndrome undergoing allogeneic transplantation with reduced-intensity conditioning.

  2024cites this paper
• Pre-transplant blinatumomab improves outcomes in B-cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation.

  2024cites this paper
• Post-transplantation cyclophosphamide and cyclosporine a versus methotrexate and cyclosporine a for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients.

  2024cites this paper
• Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study

  2024cites this paper
• Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation

  2024cites this paper
• reduced Cytokine Release Syndrome and improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplant.

  2024cites this paper
• Immunosuppression-Free Status at One-year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY).

  2024cites this paper
• Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission

  2024cites this paper
• Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantation

  2024cites this paper
• Incidence and impact of invasive fungal infection comparing post-transplant cyclophosphamide with cyclosporine plus methotrexate GVHD prophylaxis in allogeneic HSCT.

  2024cites this paper
• Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy

  2024cites this paper
• Superior survival after unrelated allogeneic stem cell transplantation with low-dose ATG compared to low-dose TBI in myeloablative fludarabine/busulfan-based regimen for MDS on behalf of the adult MDS Working Group of the JSTCT.

  2024cites this paper
• Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy

  2024cites this paper
• Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma

  2024cites this paper
• Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?

  2024influential citation
• Comparison of HLA‐haploidentical donors with post‐transplant cyclophosphamide versus HLA‐matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia

  2024cites this paper
• Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study.

  2024cites this paper
• Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial

  2024cites this paper
• PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation

  2024cites this paper
• Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period.

  2024cites this paper
• Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders

  2023cites this paper
• Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

  2023cites this paper
• Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS

  2023cites this paper
• Can the bone marrow harvest volume be reduced safely in hematopoietic stem cell transplantation with pediatric sibling donors?

  2023cites this paper
• Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation

  2023influential citation
• Extracorporeal photopheresis as graft-versus-host disease prophylaxis: a randomized controlled trial: Prophylactic extracorporeal photopheresis to prevent graft-versus-host disease.

  2023cites this paper
• Improved outcomes of UM171–expanded cord blood transplantation compared with other graft sources: real-world evidence

  2023cites this paper
• Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy

  2023cites this paper
• Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient

  2023cites this paper
• Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD

  2023cites this paper
• Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations.

  2023cites this paper
• Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.

  2023cites this paper
• Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant

  2023cites this paper
• Prognostic Value of Hematogones in Patients With Hematopoietic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

  2023cites this paper
• HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.

  2023cites this paper
• Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide.

  2023cites this paper
• Treosulfan-based conditioning regimen in pediatric hematopoietic stem cell transplantation: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).

  2023cites this paper
• Novel developments in the prophylaxis and treatment of acute GVHD.

  2023cites this paper
• The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial

  2023cites this paper
• Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation

  2023cites this paper
• Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study

  2023cites this paper